- Advertise
- About OncLive
- Editorial Board
- CancerNetwork.com
- CGTlive.com
- CureToday.com
- OncNursingNews.com
- TargetedOnc.com
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Dr Kalinsky on Unanswered Questions Regarding Genomic Testing in HR+ Breast Cancer
March 8th 2024, 8:52pm
PER® Miami Breast Cancer Conference
Kevin Kalinsky, MD, MS, discusses questions regarding the utility and implementation of genomic testing approaches in hormone receptor–positive breast cancer.
Dr Mamounas on Key Advancements in the Use of Locoregional Therapy in Breast Cancer
March 7th 2024, 11:25pm
PER® Miami Breast Cancer Conference
Terry P. Mamounas, MD, discusses key advancements in the use of locoregional therapy for patients with breast cancer.
Dr Alvarado on Selecting Breast Conservation Surgery vs Mastectomy After Neoadjuvant Therapy
March 7th 2024, 11:15pm
PER® Miami Breast Cancer Conference
Michael D. Alvarado, MD, discusses the decision to undergo breast conservation surgery vs mastectomy following neoadjuvant breast cancer therapy.
ABSK061 Demonstrates Safety, Preliminary Efficacy in FGFR2/3+ Advanced Solid Tumors
March 7th 2024, 8:00pm
ABSK061 was well tolerated and elicited responses in patients with advanced solid tumors harboring FGFR2/3 alterations.
Dr Chari on the Bridging the Gaps in Hematologic Malignancies Meeting
March 7th 2024, 6:15pm
Bridging the Gaps in Hematologic Malignancies
Ajai Chari, MD, discusses the 2024 OncLive® Bridging the Gaps in Hematologic Malignancies meeting, highlighting the treatment of multiple myeloma.
Frontline Lenvatinib Plus Pembrolizumab Generates Responses But Fails to Produce OS Benefit in HNSCC
March 5th 2024, 6:50pm
Adding lenvatinib to pembrolizumab improved ORR and PFS, but not OS, vs placebo for patients with head and neck squamous cell carcinoma.
Dr Phillips on the Treatment Landscape for Patients With MCL
March 1st 2024, 10:40pm
Bridging the Gaps in Hematologic Malignancies
Tycel Phillips, MD, discusses the landscape of treatment for patients with mantle cell.
Indirect Comparison Study Shows PFS Superiority for Zanubrutinib vs Acalabrutinib in CLL
March 1st 2024, 10:00pm
PER® Congress on Hematologic Malignancies (Winter Hematology®)
An indirect comparison study in relapsed/refractory chronic lymphocytic leukemia demonstrated survival benefits with zanubrutinib vs acalabrutinib.
Dr Danilov on Addressing Unmet Needs in Hematologic Malignancies
February 28th 2024, 10:51pm
Bridging the Gaps in Hematologic Malignancies
Alexey Danilov, MD, PhD, discusses unmet needs in hematologic malignancies to be discussed at the Bridging the Gaps in Hematologic Malignancies meeting.
Dr Saeed on the Use of Pola-R-CHP in Previously Untreated DLBCL
February 28th 2024, 10:45pm
Bridging the Gaps in Hematologic Malignancies
Hayder Saeed, MD, discusses key takeaways regarding the use of polatuzumab vedotin plus R-CHP in diffuse large B-cell lymphoma.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
February 25th 2024, 11:00am
Transplantation and Cellular Therapy Meetings
Real-world ruxolitinib use in chronic GVHD was primarily in the second- or third-line, lasted for a median of 8 months, and involved dose adjustments.
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
February 24th 2024, 8:00pm
Transplantation and Cellular Therapy Meetings
Encouraging data with RFS, OS, and NRM for Orca-T was also matched in a population of patients with hematologic cancers aged 55 years and older.
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
February 24th 2024, 5:45pm
Transplantation and Cellular Therapy Meetings
Jeremy L. Ramdial, MD, discusses the myeloablative conditioning regimen gemcitabine, clofarabine, and busulfan in patients with aggressive lymphomas.
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
February 24th 2024, 2:32pm
Transplantation and Cellular Therapy Meetings
In a retrospective analysis, Orca-T improved survival rates vs PTCy in patients with hematologic malignancies receiving myeloablative conditioning.
Dr Gomez Arteaga on an Investigation of Orca-T Vs PTCy-Based HCT in Acute Leukemia and MDS
February 24th 2024, 1:44am
Transplantation and Cellular Therapy Meetings
Alexandra Gomez Arteaga, MD, discusses a retrospective study of Orca-T vs post-transplant cyclophosphamide in acute leukemia and MDS.
Dr Banerjee on Nivolumab Use After CAR T-Cell Therapy Progression in Myeloma and NHL
February 24th 2024, 1:05am
Transplantation and Cellular Therapy Meetings
Rahul Banerjee, MD, FACP, discusses the use of nivolumab in multiple myeloma or non-Hodgkin lymphoma after progression following CAR T-cell therapy.
Dr Bertaina on T-allo10 Infusion in Young Patients With Hematologic Malignancies
February 24th 2024, 12:34am
Transplantation and Cellular Therapy Meetings
Alice Bertaina MD, PhD, discusses T-allo10 infusion post–aβdepleted-HSCT in young patients with hematologic malignancies.
Belumosudil Plus Ruxolitinib Displays Activity in Steroid-Refractory/-Dependent cGVHD
February 23rd 2024, 11:36pm
Transplantation and Cellular Therapy Meetings
Belumosudil plus ruxolitinib elicited responses with acceptable tolerability in patients with chronic graft-vs-host disease.
Dr Auletta on the Impact of Post-Transplant Cyclophosphamide in Hematologic Malignancies
February 23rd 2024, 10:19pm
Transplantation and Cellular Therapy Meetings
Jeffery Auletta, MD, discusses the impact of post-transplant cyclophosphamide in hematologic malignancies.
Dr Hamilton on HRQOL Differences With Gilteritinib Vs Placebo in Post-Transplant FLT3-ITD+ AML
February 23rd 2024, 10:18pm
Transplantation and Cellular Therapy Meetings
Betty Hamilton, MD, discusses quality of life differences between post-transplant gilteritinib vs placebo in FLT3-ITD–positive acute myeloid leukemia.